Fundraising FoxEffector Therapeutics
Solana Beach, US · Founded 2012 · Delaware corporation · 7 known investors
Find your way into Effector Therapeutics
Each arrow is one introduction. Sign up to fill in the first one.
64 people can intro you to Alana
Ask Scott Biller to introduce you to Alana McNulty
You →Scott · together at Gate Bioscience →Alana
Sign up to find every way you can get introduced to Effector Therapeutics
- Your email: who you already know at Effector Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Effector Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company. The company is no longer operating.
Founders & leadership
SF
Stephen F. Worland, Ph.D.Executive
AM
Alana McNultyExecutiveAlana McNulty held senior executive positions in biotechnology companies, including roles as Chief Business Officer, Chief Financial Officer, and General Manager, with over 35 years of industry experience. She led financing and partnership efforts including public and private capital raises, debt financings, and corporate development activities.
Board
SG
Simeon GeorgeBoard director
JR
KH
Ken HaasBoard director
LL
Laurence LaskyBoard director
MG
Markus GoebelBoard director
Investors · 7
Mission Biocapitallisted by Mission BiocapitalSan Francisco · $500K
How we know: Mission Biocapital's portfolio page · the VCSheet dataset · Not right? Tell us
OUP (Osage University Partners)listed by OUP (Osage University Partners)Bala Cynwyd · $1M – $20M
How we know: OUP (Osage University Partners)'s portfolio page · a partner's Signal profile · Not right? Tell us
Pfizer Venture Investmentslisted by Pfizer Venture Investments$5M – $20M
How we know: Pfizer Venture Investments's portfolio page · Not right? Tell us
US Venture Partnerslisted by US Venture PartnersMenlo Park · $500K – $10M
How we know: US Venture Partners's portfolio page · a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$129.4M disclosed across 4 rounds · 2013–2019
▶$20.4MraisedMay 2019 · 25 investors · BiotechnologyRule 506(b)
▶$20.4MraisedMay 2019 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Denis Patrick, Ph.D.Director
- Stephen T. Worland, Ph.D.Executive Officer, Director
- John W. SmitherDirector
- Stefan Larson, Ph.D.Director
- Alana McNultyExecutive Officer
- David Maki, J.D.Director
- Jonathan D. Root, M.D.Director
- Kenneth Haas, J.D.Director
- Simeon J. George, M.D.Director
- Laurence Lasky, Ph.D.Director
- Offering amount
- $21.8M
- Amount sold
- $20.4M
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$16.8MraisedJul 2017 · 26 investors · BiotechnologyRule 506(b)
▶$16.8MraisedJul 2017 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan D. Root, M.D.Director
- Stephen T. Worland, Ph.D.Executive Officer, Director
- Alana McNultyExecutive Officer
- Jeremy Barton, M.D.Executive Officer
- Kenneth Haas, J.D.Director
- Simeon J. George, M.D.Director
- Maha Katabi, Ph.D.Director
- David Maki, J.D.Director
- Markus Goebel, M.D., Ph.D.Director
- Elaine Jones, Ph.D.Director
- Laurence Lasky, Ph.D.Director
- Offering amount
- $38.6M
- Amount sold
- $16.8M
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$56MraisedFeb 2016 · 20 investors · BiotechnologyRule 506(b)
▶$56MraisedFeb 2016 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ken HaasDirector
- Maha KatabiDirector
- Simeon GeorgeDirector
- David MakiDirector
- Laurence LaskyDirector
- Markus GoebelDirector
- Stephen T. Worland, Ph.D.Executive Officer, Director
- Alana McNultyExecutive Officer
- Jonathan RootDirector
- Offering amount
- $56M
- Amount sold
- $56M
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$36.2MraisedJul 2015 · 15 investors · BiotechnologyRule 506(b)
▶$36.2MraisedJul 2015 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stephen F. Worland, Ph.D.Executive Officer, Director
- Alana McNultyExecutive Officer
- Simeon GeorgeDirector
- Jonathan RootDirector
- Ken HaasDirector
- Laurence LaskyDirector
- Markus GoebelDirector
- Offering amount
- $57M
- Amount sold
- $36.2M
- First sale
- May 2013
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 10
Actuate TherapeuticsActuate Therapeutics is a clinical-stage biopharmaceutical company developing elraglusib, a small-molecule GSK-3β inhibitor designed to treat difficult-to-treat cancers including pancreatic, melanoma, lung, and pediatric cancers through intravenous injection and oral tablet formulations. The company is advancing elraglusib in multiple clinical trials, with Phase 2 data in metastatic pancreatic cancer showing improved overall survival when combined with standard chemotherapy.
Electra TherapeuticsElectra Therapeutics develops antibody therapeutics targeting Signal Regulatory Protein (SIRP) for immunological diseases and cancer treatment. The company explores and validates novel drug targets with a focus on breakthrough therapies addressing underlying disease pathology.
Fate TherapeuticsFate Therapeutics develops investigational cellular immunotherapies to treat autoimmune diseases and cancer. The company is conducting clinical trials on product candidates under strict regulatory and ethical standards.
Edgewise TherapeuticsEdgewise Therapeutics discovers and develops small molecule medicines targeting muscle proteins to treat neuromuscular and cardiac diseases, including sevasemten for muscular dystrophies and EDG-7500 for cardiomyopathy, leveraging a proprietary drug discovery platform based on muscle physiology and high-throughput functional assays.
Stoke TherapeuticsStoke Therapeutics develops RNA-based antisense oligonucleotides to treat severe genetic diseases by restoring protein expression through its TANGO platform, with a lead program in late-stage clinical development for Dravet syndrome and additional programs targeting other genetic disorders of the central nervous system and eye.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Eureka TherapeuticsEureka Therapeutics is a clinical-stage biopharmaceutical company developing T-cell-based therapies to treat solid tumors and other cancers. Its pipeline is built on the ARTEMIS and E-ALPHA technology platforms aimed at targeting cancer-specific antigens.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Click TherapeuticsClick Therapeutics develops, validates, and commercializes software-based prescription medical treatments, including software-enhanced drug products that combine digital therapeutics with pharmacotherapy. It targets diseases through a platform-based approach applying neuroscience and neuromodulatory mechanisms for patients with unmet medical needs.
AlectorAlector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration. The company focuses on patients with neurodegenerative conditions and applies genetics, neuroscience, and immunology to advance new treatments.
Companies working in the same space as Effector Therapeutics.
Frequently asked questions
- What does Effector Therapeutics do?
- eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company. The company is no longer operating.
- Who are Effector Therapeutics's investors?
- Effector Therapeutics's investors include Astellas Venture Management LLC, Mission Bay Capital, Mission Biocapital, OUP (Osage University Partners), Pfizer Venture Investments, US Venture Partners, Sofinnova Ventures.
- How much funding has Effector Therapeutics raised?
- Effector Therapeutics has disclosed $129.4M raised across 4 rounds.
- Where is Effector Therapeutics headquartered?
- Effector Therapeutics is headquartered in Solana Beach, US.